APA (7th ed.) Citation

Q, H., F, T., X, W., L, Z., & X, Y. (2026). Luteolin inhibits hyperglycemia-induced epithelial-mesenchymal transition and malignant progression in gastric cancer via targeting AKR1B1-mediated glucose metabolism. Clinical & experimental metastasis, 43(4), . https://doi.org/10.1007/s10585-026-10418-w

Chicago Style (17th ed.) Citation

Q, He, Tao F, Wen X, Zhu L, and Ye X. "Luteolin Inhibits Hyperglycemia-induced Epithelial-mesenchymal Transition and Malignant Progression in Gastric Cancer via Targeting AKR1B1-mediated Glucose Metabolism." Clinical & Experimental Metastasis 43, no. 4 (2026). https://doi.org/10.1007/s10585-026-10418-w.

MLA (9th ed.) Citation

Q, He, et al. "Luteolin Inhibits Hyperglycemia-induced Epithelial-mesenchymal Transition and Malignant Progression in Gastric Cancer via Targeting AKR1B1-mediated Glucose Metabolism." Clinical & Experimental Metastasis, vol. 43, no. 4, 2026, https://doi.org/10.1007/s10585-026-10418-w.